Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 3/20 | 0.45 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | TYMP | P19971 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | IDH1 | O75874 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9111655 | 0.89 | TSHR (0.39) | DAOCAPN1TSHRHTTTYMP | |
| SCHEMBL4181067 | 0.86 | HPGD (0.45) | LMNASMN1; SMN2 | |
| SCHEMBL4176572 | 0.84 | ALDH1A1 (0.41) | DAOCAPN1TSHRHTTLMNA | |
| SCHEMBL3173218 | 0.83 | DAO (0.34) | DAOCAPN1TSHRHTTGAA | |
| SCHEMBL1268469 | 0.83 | MEN1 (0.43) | DAOTSHRLMNAMEN1GAA | |
| SCHEMBL4169393 | 0.81 | PPARG (0.43) | CAPN1HTTMEN1GAAKMT2A | |
| SCHEMBL4170750 | 0.80 | L3MBTL1 (0.45) | MEN1GAAKMT2AALDH1A1KDM4E | |
| SCHEMBL4170488 | 0.80 | L3MBTL1 (0.43) | HTTMEN1GAAKMT2AALDH1A1 | |
| SCHEMBL2257130 | 0.77 | DAO (0.49) | DAOHTTTYMPLMNAHSD17B10 | |
| SCHEMBL6135082 | 0.77 | DAO (0.49) | DAOHTTTYMPLMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1864993-B1 | PROCESS FOR PRODUCTION OF GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVE | KISSEI PHARMACEUTICAL (JP) | 2012-05-16 | — | — | EP | disclosed |
| US-8022192-B2 | Process for production of glucopyranosyloxypyrazole derivative | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-09-20 | — | — | US | disclosed |
| US-20110201793-A1 | PROCESS FOR PRODUCTION OF GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVE | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-08-18 | — | — | US | disclosed |
| US-20090062518-A1 | PROCESS FOR PRODUCTION OF GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVE | KISSEI PHARMACEUTICAL CO., LTD, (JP) | 2009-03-05 | — | — | US | disclosed |
| EP-1864993-A1 | PROCESS FOR PRODUCTION OF GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVE | Kissei Pharmaceutical Co., Ltd. (JP) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201793-A1 | PROCESS FOR PRODUCTION OF GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVE | GCGR, UGGT1, GCKR | DAO 1503/4885CAPN1 3599/4885TSHR 958/4885 |
| US-20090062518-A1 | PROCESS FOR PRODUCTION OF GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVE | GCGR, UGGT1, GCKR | DAO 1503/4885CAPN1 3599/4885TSHR 958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.